http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Apr 2026 12:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Press+Releases/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html <p><b>Allschwil, Switzerland, April 15, 2026</b></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM).</p> <p>Shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2025. They also endorsed carrying forward the accumulated profit and approved the discharge of the members of the board of directors and the management committee. </p> <p>Mr. Stephan Schindler was re-elected as chairman and Mr. http://www.streetinsider.com/Globe+Newswire/Basilea+shareholders+approve+all+proposals+of+the+board+of+directors+at+the+2026+annual+general+meeting/26317328.html Wed, 15 Apr 2026 12:30:00 -0400 A.26518865 BSLN O.00222785 O.01856175 http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Press+Releases/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html <p><strong>Allschwil, Switzerland, February 09, 2026</strong></p> <p>Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole), by its license partner Pfizer Inc. in the Asia Pacific region and China, exceeded the sales threshold triggering a USD 5 million milestone payment. </p> <p>David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This milestone payment reflects the significant http://www.streetinsider.com/Globe+Newswire/Strong+Cresemba%C2%AE+%28isavuconazole%29+sales+performance+in+Asia+Pacific+and+China+triggers+milestone+payment+to+Basilea/25963659.html Mon, 09 Feb 2026 01:15:00 -0400 A.38055885 BSLN O.00222785 O.01691593 http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877 http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.union" idsrc="xmltag.org" >UNION, N.J.</location></span>, <span class="legendSpanClass"><chron>Jan. 7, 2026</chron></span> /PRNewswire/ -- <span>Prokaryotics Inc.</span>, a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement with <span>Basilea Pharmaceutica Ltd</span>, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Prokaryotics+and+Basilea+enter+collaboration+to+develop+a+novel+broad-spectrum+antifungal+for+severe+invasive+infections/25815785.html Wed, 07 Jan 2026 01:15:00 -0400 A.17568957 A.38055885 BSLN O.01691593 O.04889877